1. Introduction {#sec1}
===============

Intensive glycemic control delays and prevents microvascular and macrovascular complications of type 1 diabetes (T1DM) \[[@B1], [@B2]\]. Despite advances in insulin preparations and delivery mechanisms for insulin, glycemic control for many pediatric patients with T1DM remains suboptimal. An international study comparing glycemic control among pediatric diabetes centres failed to show a correlation with insulin regimen, suggesting that other factors, such as the organization of delivery of care and the number of staff on the diabetes team, may be critical to attaining optimal blood glucose control \[[@B3]\].

The intensive treatment protocol used in the Diabetes Control and Complications Trial (DCCT) included telephone contacts to adjust insulin regimens daily for the first week and then weekly thereafter. The intervention also involved an intensive insulin regimen, increased frequency of clinic visits, and intensive blood glucose monitoring \[[@B4]\]. Although shown to be effective in improving glycemic control, these intensive measures are not feasible to carry out in routine practice.

Moreover, the particular challenges presented by youth with T1DM necessitate innovative management strategies \[[@B5]\]. One strategy for improving glycemic control is the use of telemedicine (TM). We distinguish routine T1DM management that may include solicited remote communication between patients and the diabetes team on an as-needed basis from TM interventions as defined in our study. We define TM to be the scheduled remote transmission of blood glucose (BG) data by means such as telephone, fax, mobile phone, or internet with unsolicited clinician feedback. This definition of TM is consistent with that used previously by authors of systematic reviews on this topic in the adult population with T1DM \[[@B6]\].

The impact of these types of interventions on the management of youth with T1DM is unknown. A previous systematic review that included studies published up to July 2004 in adults and youth with all types of diabetes \[[@B7]\] and another that included studies up to June 2003 in adults and youth with T1DM \[[@B6]\] both report no effect of TM on glycemic control. Since that time, new technologies such as short message service (SMS) have become more widely accessible to and utilized by youth.

Our objective is to assess the impact of TM interventions on glycemic control in youth with T1DM. We report the results of an updated systematic review that includes seven new randomized trials, focuses only on the impact of TM for T1DM in youth, and uses rigorous methodology. We also identify a need to obtain additional data on potential benefits of using telemedicine in clinical practice that extend beyond its impact on glycemic control, including engaging and empowering adolescents with novel technologies, improving patient and family quality of life, and enhancing patient and family education.

2. Methods {#sec2}
==========

MEDLINE, EMBASE, CCTR, CINAHL (EBSCOHost), ISI Web of Science, and [clinicaltrials.gov](http://clinicaltrials.gov/) were searched up to December 21, 2009 without language restriction. Available indexing terms and text words for T1DM, TM, or related terms, and randomized controlled (RCT) or controlled clinical trials (CCT) were used. The Telemedicine Information Exchange (an international searchable database of telemedicine citations), relevant conference abstracts from 2007-2008, and reference lists of included studies were also searched.

Eligibility criteria for study inclusion were (1) youth less than 19 years with T1DM; (2) TM interventions involving scheduled routine transmission of blood glucose (BG) data with unsolicited scheduled clinician feedback; (3) inclusion of a control group that did not receive unsolicited feedback about transmitted BG data; (4) RCT or CCT. Studies were excluded if participants were pregnant or had non-T1DM. Two reviewers independently assessed studies for eligibility and validity and extracted data. Disagreements were resolved through consultation with a third reviewer. Assessment of study validity was done using the Cochrane Collaboration\'s tool for assessing risk of bias \[[@B8]\]. The Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) system was used to assess the quality of the body of evidence.

The primary outcome assessed was HbA1c as a marker of long-term complications of diabetes. Treatment effect was expressed as a mean difference with 95% CI for continuous outcomes and as an odds ratio (OR) with 95% CI for dichotomous outcomes. Meta-analyses using a random-effects model were performed using Review Manager Version 5.0 software. We used the *I*^2^ statistic to determine the proportion of variation in study estimates due to heterogeneity. Publication bias was assessed using funnel plots.

We hypothesized, *a priori*, that the following factors may explain heterogeneity (variability in participants, interventions, outcomes, study design, and risk of bias among studies): (1) age, (2) baseline HbA1c, (3) frequency of data transmission, and (4) timing of outcome measurement. Insufficient data prohibited within-study comparisons to test these hypotheses; however, between-study comparisons were performed.

3. Results {#sec3}
==========

Of 434 studies identified, 377 were excluded after review of titles and abstracts because they were duplicates or involved the wrong population, intervention, and/or study design; 57 studies were retrieved in full text. Ten studies, involving 609 youth, met eligibility criteria \[[@B10]--[@B9]\] (see [Figure 1](#fig1){ref-type="fig"} for details of the process of the selection of studies for inclusion and [Table 1](#tab1){ref-type="table"} for study characteristics). Data from nine of the ten studies were included in the meta-analysis. Data from one study \[[@B18]\] was excluded because the primary outcome, HbA1c, was reported as a modeled HbA1c effect and therefore could not statistically be combined with outcomes reported in the other studies. We report the results from this study separately.

The shortest study lasted 3 months and the longest 12 months. Most studies were 6 months in duration. All studies involved a minimum of every two-week frequency of data transmission except one that had a school-based monthly videoconference \[[@B18]\]. Clinic visits were held every three months, except in one study \[[@B12]\] in which patients attended clinic only every 6 months ([Table 1](#tab1){ref-type="table"}). Most studies used telephone, modem, or fax to transmit data. One \[[@B9]\] used SMS, and one used videoconference \[[@B18]\]. The mean age of all participants ranged from 10 to 17 years. Most studies limited inclusion criteria to participants with suboptimal glycemic control. The mean baseline HbA1c in the studies included in the meta-analysis ranged from 8.2% to 10.2% ([Table 2](#tab2){ref-type="table"}).

For all outcomes, the quality of the body of evidence was downgraded because of elements of study design and execution ([Table 3](#tab3){ref-type="table"}) and because the GRADE system to assess quality of evidence necessitates a downgrade for the use of any indirect measure, such as HbA1c as a marker for long-term complications \[[@B8]\]. The evidence regarding severe hypoglycemia and DKA was also downgraded because rare event rates and wide confidence intervals reflect uncertainty about the estimate of effect. Therefore, for glycemic control, severe hypoglycaemia, and DKA, the quality evidence is graded as low ([Table 4](#tab4){ref-type="table"}).

There was no statistically significant effect of TM on HbA1c (mean difference −0.12, 95% CI, −0.35 to 0.11) with no contribution of statistical heterogeneity to the variability in effect estimate (*I*^2^ = 0%) ([Figure 2(a)](#fig2){ref-type="fig"}). Data from the single study not included in the meta-analysis \[[@B18]\] showed a significant difference in slope of the modelled HbA1c effect between the TM and control groups during the first six months of the intervention (*P* \< .02), but none after the six month point. The absolute decrease in the modelled HbA1c in the TM group at six months was less than 0.5%.

Between-study comparisons based on age, baseline HbA1c, frequency of data transmission, and timing of HbA1c measurement revealed no differences in pooled estimates between subgroups. A post hoc between-study comparison based on whether feedback was given in real-time or if it was stored and forwarded also found no difference in HbA1c at the end of the intervention. The pooled estimate for a between-study analysis comparing studies with mean baseline HbA1c values \<9.0% to those with ≥9.0% trended toward favoring TM in the subgroup of studies with baseline HbA1c ≥9% ([Figure 3](#fig3){ref-type="fig"}). Publication bias was unlikely based on visual examination of the funnel plot.

Five studies reported frequency of severe hypoglycaemia and DKA \[[@B10], [@B13], [@B18], [@B16], [@B9]\]. The pooled estimates revealed no effect on severe hypoglycemia (OR 1.42, 95% CI, 0.22 to 9.32) or DKA (OR 1.02, 95% CI, 0.24 to 4.23) (Figures [2(b)](#fig2){ref-type="fig"} and [2(c)](#fig2){ref-type="fig"}). A sensitivity analysis including data from the study not included in the meta-analysis \[[@B18]\] did not significantly change the pooled estimate for severe hypoglycemia or DKA.

However, the school-based study did find a decrease in urgent visits to the school nurses for diabetes-related problems and urgent calls to the diabetes center in the TM group compared to control \[[@B18]\]. Of studies included in the meta-analysis, patient satisfaction could be assessed in only one study \[[@B13]\] and showed no significant difference between groups. The school-based study \[[@B18]\] assessed patient satisfaction in the intervention group only and found that 91% of participants would use the telemedicine services again. Three studies reported diabetes-related quality of life (QoL) \[[@B18]--[@B14]\], and none found significant differences between groups. Only two studies \[[@B10], [@B13]\] reported the cost of a clinic visit; in one of these \[[@B13]\], the TM group did not attend the three-month visit with a cost savings of \$USD 142.00. Indirect costs such as missed work and school were considered \[[@B13]\] but not converted into dollar value nor incorporated in the overall cost calculation.

4. Discussion {#sec4}
=============

Our results indicate that, despite a significant increase in new studies, no robust effect of TM on HbA1c was observed at the end of the intervention. It remains possible that TM has a small effect on HbA1c, but our data argue against a large effect. Our pooled analysis includes more than 100 subjects per group giving us enough power to detect a difference in HbA1c of 0.5%. Therefore, if there is an effect of the intervention on HbA1c, it is likely less than 0.5%. Our results are consistent with a recent randomized control trial examining the effect of telemedicine case management for diabetes in an older population. This study involving 1,665 subjects found an estimated 0.29% difference in HbA1c favoring telemedicine at the end of 5 years between groups \[[@B19]\].

We do not believe that lack of effect stems from selection bias among included studies. We did not expand our definition to include all uses of telemedicine, including web-based education modules and teleconferences to conduct remote clinic visits that did not necessarily include routine transmission of and feedback on blood glucose results, because that would have resulted in a collection of heterogeneous interventions among which a combination and comparison of outcomes would have been inappropriate in a meta-analysis. Moreover, upon reviewing studies that were excluded by our methods, we found that the results of those studies excluded were similar to those that were included. Three randomized controlled trials that were excluded from our review, because they did not involve transmission of blood glucose data, also found no effect on glycemic control \[[@B20]--[@B22]\].

Episodes of severe hypoglycemia and DKA were rare and did not differ between groups. Although data were limited, there were no apparent differences in QoL or patient satisfaction between groups. One study that used TM to replace a clinic visit suggests a reduction in cost with no increase in adverse effects. Although we might have expected adolescents to be more engaged in a telemedicine intervention compared to younger children, a between-study comparison found no differences in pooled estimates of HbA1c at the end of the intervention between subgroups based on age. However, it is possible that future, more technology-based interventions may fare better.

We used the GRADE system because it provides explicit and comprehensive criteria for assessing the quality of a body of evidence. We recognize that based on this system, the evidence in our study was determined to be low. This was, in part, due to a necessary downgrade for the use of HbA1c as an indirect measure. However, based on the results of the DCCT \[[@B1], [@B2]\], HbA1c is regarded as a reliable surrogate marker for long-term complications in T1DM. Therefore, the quality of evidence is likely better than is reflected by the GRADE system.

Despite disappointing initial results, many aspects of TM interventions warrant further study. For example, between-study subgroup analyses suggest a trend toward a greater effect of TM on HbA1c among participants with the highest baseline HbA1c. Thus, determining whether TM could be an important adjunct for patients with the poorest glycemic control is worth further investigation in well designed, adequately powered, long-term studies.

Although our study found no overall effect on glycemic control, it did not identify any detrimental effects. Thus, other factors to consider include whether TM may be more effective in subgroups of youth such as those living remotely from the centres where care is provided. Reducing the number of clinic visits, while maintaining glycemic control, would be clinically desirable and potentially cost-effective. Thus, more studies are also needed to examine the cost-utility of TM and to determine the effects of TM interventions that replace aspects of diabetes care. Such studies should consider if TM would result in missed opportunities for screening for complications and/or education.

Finally, it will also be important to determine whether the effect of TM differs depending on the expertise of the individuals administering the TM, the frequency, and mode of data transmission (SMS, email, mobile phone, smart phone, personal digital assistant (PDA)) and whether the intervention involves the youth and/or their caregivers, or the setting. One study that examined TM in the school setting found that there was a decrease in the number of urgent visits to school nurses and calls to the diabetes centers. Successful implementation of a school-based TM intervention depends on the particular structure of the school system and may not be feasible where there are no school nurses.

It was surprising that more of the recent studies did not use more novel modes of data transmission such as SMS or other telephone-based strategies. It is possible that future studies examining the effects of newer technologies may show different results compared to the studies currently available for review. In addition to glycemic control and complications, such studies should measure other patient-important outcomes such as QoL, diabetes knowledge, and patient satisfaction.

5. Conclusions {#sec5}
==============

In its recommendations about the structure of pediatric diabetes care the International Society for Pediatric and Adolescent Diabetes (ISPAD) recommends the use of TM for patients living remotely from diabetes centres and acknowledges that TM may result in improved diabetes management in all areas \[[@B5]\]. Our paper will likely not change current practice as diabetes care clinics will have to embrace these novel forms of communication to mirror what patients are using. Because of the small number and variable nature of the available studies, we have tried to be careful not to overinterpret our results. However, given the potential monetary and personnel costs involved in implementing TM strategies, our paper does emphasize that TM should be well studied before it is embraced and that care must be taken to identify which subgroups of patients would maximally benefit and how we should deliver TM in the most time and resource efficient manner.

Elizabeth Uleryk, Library Director at The Hospital for Sick Children, was instrumental in developing the search strategy. We also thank Drs. Farid Mahmud and Denis Daneman for helpful comments and critical review of the paper.
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![Process of selection of studies for inclusion.](IJPE2010-536957.001){#fig1}

![Meta-analysis of the effect of TM. Weight assigned to each study was determined using the inverse variance (IV) method which assigns weight based on the inverse of the variance of the effect estimate (one over the square of the standard error). Studies with smaller standard errors are given more weight than those with larger standard errors \[[@B25]\]. The size of the square representing the measure of effect is proportional to the percent weight assigned to each study on the forest plot.](IJPE2010-536957.002){#fig2}

![Meta-analysis of HbA1c at the end of the intervention with between-study comparison based on baseline HbA1c values. Weight assigned to each study was determined using the inverse variance (IV) method which assigns weight based on the inverse of the variance of the effect estimate (one over the square of the standard error). Studies with smaller standard errors are given more weight than those with larger standard errors \[[@B25]\]. The size of the square representing the measure of effect is proportional to the percent weight assigned to each study on the forest plot.](IJPE2010-536957.003){#fig3}

###### 

Study characteristics of the 10 studies that met inclusion criteria.

  Lead author, year (ref)            Sample size   Frequency and mode of data transmission and feedback                                                                     Duration (months)   Cointerventions                                                         Frequency of clinic visits (months)       Study design
  ---------------------------------- ------------- ------------------------------------------------------------------------------------------------------------------------ ------------------- ----------------------------------------------------------------------- ----------------------------------------- ----------------------------------------
  Cadario, 2007 \[[@B10]\]           28            2 weeks via modem, clinician within 1 week                                                                               6                   None                                                                    3                                         RCT
  Chase, 2000 \[[@B13]\]             70            2 weeks via modem, clinician by telephone                                                                                6                   None                                                                    3 (TM group did not attend at 3 months)   RCT
  Gay, 2006 \[[@B15]\]               100           2 weeks, printout of glucometer data faxed, pediatric endocrinologist advice by mail or phone within 5 days              6                   None                                                                    3                                         RCT
  Howe, 2005 \[[@B11]\]              75            TM plus ED: weekly phone calls for 3 months, then bimonthly for 3 months with diabetes nurse educator                    6                   Education session                                                       3                                         RCT, 3-arms
  Izquierdo, 2009 \[[@B18]\]         41            Monthly videoconference with immediate feedback                                                                          12                  Education modules                                                       3                                         RCT, randomization at the school level
  Lawson, 2005 \[[@B16]\]            46            Weekly telephone contact with diabetes nurse educator                                                                    6                   None                                                                    3                                         RCT, single-blinded, parallel design
  Marrero, 1995 \[[@B14]\]           106           2 weeks, data management system reviewed by clinician, feedback frequency determined by algorithms                       12                  None                                                                    3                                         RCT, repeated measures design
  Nunn, 2006 \[[@B17]\]              123           Bimonthly phone calls with nurse educator                                                                                5--8                Educational program by phone using written material and illustrations   3                                         RCT
  Panagiotopoulos, 2003 \[[@B12]\]   50            Phone contact with educator 1-2 times weekly                                                                             6                   Education provided during calls and teen issues addressed               6                                         RCT
  Rami, 2006 \[[@B9]\]               36            Every BG checked or at least daily via short message service (SMS), reviewed weekly by diabetologist with SMS feedback   3                   None                                                                    3                                         Randomized cross-over trial

###### 

HbA1c at baseline and at end of intervention of the 9 studies included in the meta-analysis.

  Study             HbA1c Inclusion criteria   Mean (SD) HbA1c baseline control (%)   Change in mean HbA1c at followup control (%)   Mean (SD) HbA1c baseline TM (%)   Change in mean HbA1c at followup TM (%)
  ----------------- -------------------------- -------------------------------------- ---------------------------------------------- --------------------------------- -----------------------------------------
  Cadario           \>7.0%                     \*9.2                                  +0.2                                           \*9.1                             0
  Chase             7.0%--13.0%                8.9 (1.1)                              −0.3                                           9.0 (1.2)                         −0.4
  Gay               ≥8.0%                      9.2 (0.9)                              +0.1                                           9.3 (1.3)                         −0.2
  Howe              \>8.5%                     10.2 (1.4), ED 10.1 (1.2)              −0.5                                           10.0 (1.4)                        −0.5
  Lawson            \>8.5%                     9.7 (0.6)                              −0.1                                           10.0 (1.3)                        −0.6
  Marrero           None defined               9.9 (1.6)                              +0.4                                           9.4 (1.9)                         +0.6
  Nunn              \>8.0%                     8.3 (1.0)                              +0.5                                           8.2 (1.1)                         +0.7
  Panagiotopoulos   ≥8.0% but \<14.0%          9.6 (1.3)                              −0.5                                           9.7 (1.2)                         −0.9
  Rami              ≥8.0%                      ^†^9.3 (8.3--11.6)                     +0.4                                           ^†^9.1 (8.0--11.3)                −0.1

ED: education.

\*No measure of variance reported.

^†^Median (range).

###### 

Risk of Assessment of Bias of the 10 studies that met inclusion criteria.

  Study                  Sequence generation   Allocation concealment   Blinding of healthcare providers   Blinding of data collectors   Blinding of data analyzers   Incomplete outcome data   Selective outcome reporting
  ---------------------- --------------------- ------------------------ ---------------------------------- ----------------------------- ---------------------------- ------------------------- -----------------------------
  Cadario 2007           Unsure                Unsure                   Unsure                             Unsure                        Unsure                       Inadequate                Adequate
  Chase 2003             Unsure                Unsure                   Adequate                           Unsure                        Unsure                       Inadequate                Adequate
  Gay 2006               Adequate              Unsure                   Unsure                             Unsure                        Unsure                       Inadequate                Inadequate
  Howe 2005              Adequate              Unsure                   Unsure                             Unsure                        Unsure                       Inadequate                Adequate
  Izquierdo 2009         Unsure                Unsure                   Unsure                             Unsure                        Unsure                       Inadequate                Adequate
  Lawson 2005            Adequate              Adequate                 Adequate                           Adequate                      Adequate                     Adequate                  Adequate
  Marrero 1995           Unsure                Unsure                   Unsure                             Unsure                        Unsure                       Unsure                    Adequate
  Nunn 2006              Adequate              Unsure                   Inadequate                         Unsure                        Unsure                       Adequate                  Adequate
  Panagiotopoulos 2003   Adequate              Unsure                   Unsure                             Unsure                        Unsure                       Adequate                  Inadequate
  Rami 2006              Unsure                Unsure                   Unsure                             Unsure                        Unsure                       Adequate                  Adequate

Refer to the Cochrane Collaboration\'s tool for assessing risk of bias \[[@B8]\] for the methods used to assess the risk of bias in studies.

###### 

GRADE Evidence Profile Summarizing the Effect of TM versus Control.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Quality assessment                                      Summary of findings                                                                                                                                                                              
  ------------------------------------------------------- --------------------- ------------ --------------- -------------- ------------- ------ ------------- ------------- ----------------------- --------------------------------------------- ------- ----------
  HbA1c at closest point in time to end of intervention                                                                                                                                                                                                    

                                                                                                                                                                                                                                                           

  7                                                       Randomised trials     Serious^1^   No serious\     Serious^2^     No serious\   None   243           242           ---                     MD 0.13 lower (0.36 lower to 0.11 higher)     ⨁⨁OO\   Critical
                                                                                             inconsistency                  imprecision                                                                                                            LOW     

                                                                                                                                                                                                                                                           

  Severe Hypoglycemia                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                           

  4                                                       Randomised trials     Serious^1^   No serious\     No serious\    Serious^3^    None   1/85 (1.2%)   0/68 (0%)     OR 2.78 (0.1 to 74.7)   0 more per 1000 (from 0 fewer to 0 more)      ⨁⨁OO\   Critical
                                                                                             inconsistency   indirectness                                                                                                                          LOW     

                                                                                                                                                                                                                                                           

  Diabetic Ketoacidosis                                                                                                                                                                                                                                    

                                                                                                                                                                                                                                                           

  4                                                       Randomised trials     Serious^1^   No serious\     No serious\    Serious^3^    None   2/85 (2.4%)   2/86 (2.3%)   OR 1.05 (0.14 to 7.8)   1 more per 1000 (from 20 fewer to 133 more)   ⨁⨁OO\   Critical
                                                                                             inconsistency   indirectness                                                                                                                          LOW     
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

MD: mean difference.

OR: odds ratio.

^1^Plausible bias that seriously weakens confidence in the results.

^2^HbA1c is a surrogate marker of long-term complications of diabetes.

^3^Events were rare, and CI are wide around the estimate of effect.

[^1]: Academic Editor: Stuart A. Weinzimer
